Clinical policy for prescribing of masculinising and feminising hormones for children and adolescents who have gender incongruence or dysphoria

Overview

NHS England is committed to working with a wide range of patients, patient groups and other stakeholders in developing the services it commissions.

In line with NHS England’s published methods for the formation of national clinical commissioning policy, public consultation presents an important step in the process. It allows us to test and get feedback on proposals; check that draft policies are well evidenced; ensure potential impacts have been fully captured, are clearly understood and that appropriate mitigations have been identified; and, consider alternatives before final decisions are taken.

NHS England commissions the specialised NHS Children and Young People’s Gender Service, which sees children and young people up to 18 years. The purpose of this consultation is to seek views on a revised clinical policy on masculinising and feminising (MAF) hormones for children and adolescents who have gender incongruence or dysphoria.

On the advice of NHS England’s Patient and Public Voice Assurance Group for specialised commissioning, this public consultation will run for 90 days from 9 March to 7 June 2026.

At the end of the consultation period, all feedback will be considered before the clinical policy is published.

We recommend that you read this consultation guide alongside the other documents published as part of the consultation. While this consultation guide has been produced to summarise the proposals, the other documents provide additional detail.

Consultation documents

• Consultation guide
• Draft policy proposition
• Draft equality and health inequalities impact assessment
• Evidence reviews
• Population, intervention,comparator and outcomes (PICO)
• Excluded papers